Viking Therapeutics Launches Phase 1 VK3019 Obesity Trial in Adults with BMI ≥30
VKTX•Viking Therapeutics has initiated a randomized, double-blind, placebo-controlled Phase 1 single ascending dose trial of VK3019 in healthy adults with BMI ≥30 after FDA clearance of its IND application. Preclinical DACRA data showed up to 8% body weight reduction and suppressed food intake in obese mice within 72 hours.
1. Phase 1 Trial Initiation
Viking Therapeutics has begun a randomized, double-blind, placebo-controlled single ascending dose study of VK3019 in healthy adults with BMI ≥30 following FDA IND clearance. The trial will assess safety, tolerability and pharmacokinetics of single subcutaneous doses and include exploratory evaluations of weight change after dosing.
2. Preclinical Efficacy Data
Preclinical studies of VK3019’s dual amylin and calcitonin receptor agonist mechanism demonstrated reductions in food intake within 72 hours and up to 8% body weight loss in diet-induced obese mice compared with controls, supporting its weight loss potential in humans.
3. Pipeline and Future Trials
Alongside VK3019, Viking is advancing its Phase 3 VANQUISH program evaluating VK2735, a GLP-1/GIP dual agonist, in weekly subcutaneous injection trials and an oral tablet formulation. The company plans to start a Phase 3 oral VK2735 trial later this year and report novel dosing regimen data in 3Q26.
4. Market Potential and Differentiation
VK3019’s dual receptor agonist profile could complement existing GLP-1 or dual GLP-1/GIP therapies to enhance induction and maintenance of weight loss, positioning Viking to address the growing obesity market with differentiated treatment options.
